Abstract
Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 883-896 |
| Number of pages | 14 |
| Journal | OncoTargets and Therapy |
| Volume | 12 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Apoptosis
- CTS
- ESCC
- Migration
- Proliferation
- Xenograft
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation. / Ji, Yubin; Liu, Yichen; Xue, Nina; Du, Tingting; Wang, Liyuan; Huang, Rui; Li, Ling; Yan, Chunhong; Chen, Xiaoguang.
In: OncoTargets and Therapy, Vol. 12, 01.01.2019, p. 883-896.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation
AU - Ji, Yubin
AU - Liu, Yichen
AU - Xue, Nina
AU - Du, Tingting
AU - Wang, Liyuan
AU - Huang, Rui
AU - Li, Ling
AU - Yan, Chunhong
AU - Chen, Xiaoguang
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.
AB - Purpose: Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of esophageal cancer, with a poor clinical outcome. Cryptotanshinone (CTS) is the main bioactive compound from the root of Salvia miltiorrhiza Bunge. Our study aimed to investigate the anti-cancer effects and molecular mechanisms of CTS on ESCC. Materials and methods: We investigated the anti-tumor activity of CTS on ESCC in vitro and in vivo. Activation of the STAT3 signaling pathway was evaluated in ESCC and HEK-Blue™ IL-6 cells. Cell viability was assessed by the MTT assay. Apoptosis and cell cycle arrest were assessed using flow cytometry. Cell migration was detected by a scratch wound assay. Results: CTS inhibited STAT3 expression and IL-6-mediated STAT3 activation in esophageal cancer cells. Subsequently, CTS dose-dependently inhibited the proliferation of esophageal cancer cells via induction of cell apoptosis. Furthermore, CTS suppressed the migration of esophageal cancer cells. In vivo, CTS inhibited tumor growth of EC109 cell in xenograft mice without any obvious effect on body weight. Conclusion: Our results indicated that STAT3 inhibition may be a therapeutic target for esophageal cancer. CTS could provide a potential approach for esophageal cancer therapy by influencing the janus kinase-2/STAT3 signaling pathway.
KW - Apoptosis
KW - CTS
KW - ESCC
KW - Migration
KW - Proliferation
KW - Xenograft
UR - http://www.scopus.com/inward/record.url?scp=85062698391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062698391&partnerID=8YFLogxK
U2 - 10.2147/OTT.S187777
DO - 10.2147/OTT.S187777
M3 - Article
AN - SCOPUS:85062698391
VL - 12
SP - 883
EP - 896
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
SN - 1178-6930
ER -